The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).
--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. The company’s lead product candidate, maralixibat, is an investigational oral drug in development for progressive familial intrahepatic cholestasis (PFIC) and Alagille syndrome (ALGS).
| Company: | Mirum Pharmaceuticals | |
|
|
| |
| Headquarters Address: | 950 Tower Lane | |
|
| Suite 1050 | |
|
| Foster City, CA 94404 | |
|
|
| |
| Main Telephone: | 650-667-4085 | |
|
|
| |
| Website: | ||
|
|
| |
| Ticker: | MIRM(NASDAQ) | |
|
|
| |
| Type of Organization: | Public | |
|
|
| |
| Industry: | Biotechnology | |
|
|
| |
| Key Executives: | CFO: Ian Clements | |
|
|
| |
| Investor Relations |
| |
| Contact: | Ian Clements | |
| Email: |
View source version on businesswire.com: https://www.businesswire.com/news/home/20190926005500/en/
Source: Mirum Pharmaceuticals, Inc.
View this news release online at:
http://www.businesswire.com/news/home/20190926005500/en
